CN107427460A - 溴莫尼定和噻吗洛尔的固定剂量组合 - Google Patents

溴莫尼定和噻吗洛尔的固定剂量组合 Download PDF

Info

Publication number
CN107427460A
CN107427460A CN201680015524.5A CN201680015524A CN107427460A CN 107427460 A CN107427460 A CN 107427460A CN 201680015524 A CN201680015524 A CN 201680015524A CN 107427460 A CN107427460 A CN 107427460A
Authority
CN
China
Prior art keywords
composition
timolol
brimonidine
tartrates
maleates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680015524.5A
Other languages
English (en)
Chinese (zh)
Inventor
J·焦
张金明
A·V·戈雷
R·S·格雷厄姆
R·S·乔丹
S·尼尔万南
C·P·普亚拉
沈洁
K·S·瓦纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN107427460A publication Critical patent/CN107427460A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
CN201680015524.5A 2015-03-19 2016-03-17 溴莫尼定和噻吗洛尔的固定剂量组合 Pending CN107427460A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562135320P 2015-03-19 2015-03-19
US62/135,320 2015-03-19
PCT/US2016/022874 WO2016149498A1 (en) 2015-03-19 2016-03-17 Fixed dose combination of bromonidine and timolol

Publications (1)

Publication Number Publication Date
CN107427460A true CN107427460A (zh) 2017-12-01

Family

ID=55640942

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680015524.5A Pending CN107427460A (zh) 2015-03-19 2016-03-17 溴莫尼定和噻吗洛尔的固定剂量组合

Country Status (9)

Country Link
US (3) US20180078500A1 (https=)
EP (2) EP3270892B1 (https=)
JP (4) JP7199146B2 (https=)
KR (1) KR20170129823A (https=)
CN (1) CN107427460A (https=)
AU (3) AU2016233125A1 (https=)
CA (1) CA2977825A1 (https=)
HK (1) HK1246689A1 (https=)
WO (1) WO2016149498A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115671037A (zh) * 2022-11-21 2023-02-03 山东诺明康药物研究院有限公司 一种溴莫尼定噻吗洛尔pH敏感型原位凝胶及其制备方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7170436B2 (ja) * 2017-06-28 2022-11-14 千寿製薬株式会社 水溶性高分子を含む点眼剤
WO2019112030A1 (ja) * 2017-12-08 2019-06-13 千寿製薬株式会社 水溶性高分子を含む水性液剤
WO2019216395A1 (ja) * 2018-05-11 2019-11-14 千寿製薬株式会社 眼科用組成物
WO2019223748A1 (zh) * 2018-05-25 2019-11-28 爱博诺德(北京)医疗科技股份有限公司 粘弹剂材料
JP7630944B2 (ja) * 2019-09-12 2025-02-18 千寿製薬株式会社 ブリモニジンとチモロールとを含む、緑内障罹患患者における眼圧を下降させるための組成物
GR1010024B (el) * 2020-05-06 2021-06-01 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση που περιλαμβανει βριμονιδινη
WO2023086878A1 (en) 2021-11-10 2023-05-19 Visus Therapeutics, Inc. Carbachol formulations to enhance anti-presbyopia effects

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003088973A1 (en) * 2002-04-19 2003-10-30 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
WO2012016000A2 (en) * 2010-07-29 2012-02-02 Allergan, Inc. Preservative free brimonidine and timolol solutions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003198C (en) * 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
CA2416169C (en) * 2000-07-14 2008-09-23 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
PL360707A1 (en) * 2000-07-14 2004-09-20 Allergan Inc. Compositions containing alpha-2-adrenergic agonist components
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
CA2505836C (en) * 2004-05-06 2013-08-27 Alcon Inc. Topical brimonidine tartrate formulations that lack chlorine dioxide
DK2377557T3 (en) 2004-11-24 2017-02-06 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods for its use
US20070238732A1 (en) * 2006-04-10 2007-10-11 Allergan, Inc. Brimonidine and timolol compositions
WO2008024846A2 (en) * 2006-08-25 2008-02-28 Allergan, Inc. Brimonidine and timolol compositions
MX2012007397A (es) * 2009-12-22 2012-08-15 Allergan Inc Composiciones y metodos para reducir la presion intraocular.
JP2014501748A (ja) 2010-12-21 2014-01-23 リコファーマ アーベー 涙代用物
ES2818073T3 (es) * 2013-12-24 2021-04-09 Sentiss Pharma Private Ltd Solución oftálmica de tartrato de brimonidina tópica
US20160331746A1 (en) * 2015-05-12 2016-11-17 University Of South Florida Sortilin-Binding Small Molecules for Increasing Glucose Uptake

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003088973A1 (en) * 2002-04-19 2003-10-30 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
WO2012016000A2 (en) * 2010-07-29 2012-02-02 Allergan, Inc. Preservative free brimonidine and timolol solutions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115671037A (zh) * 2022-11-21 2023-02-03 山东诺明康药物研究院有限公司 一种溴莫尼定噻吗洛尔pH敏感型原位凝胶及其制备方法

Also Published As

Publication number Publication date
EP4420726A2 (en) 2024-08-28
US20250387325A1 (en) 2025-12-25
CA2977825A1 (en) 2016-09-22
EP4420726A3 (en) 2024-11-13
JP2021102626A (ja) 2021-07-15
US20180078500A1 (en) 2018-03-22
JP2018508545A (ja) 2018-03-29
EP3270892B1 (en) 2024-04-10
AU2023208076A1 (en) 2023-08-10
WO2016149498A1 (en) 2016-09-22
US20220370346A1 (en) 2022-11-24
KR20170129823A (ko) 2017-11-27
AU2021203665A1 (en) 2021-09-02
JP7199146B2 (ja) 2023-01-05
JP2025100564A (ja) 2025-07-03
AU2016233125A1 (en) 2017-09-14
EP3270892A1 (en) 2018-01-24
HK1246689A1 (zh) 2018-09-14
JP2023086773A (ja) 2023-06-22

Similar Documents

Publication Publication Date Title
US20250387325A1 (en) Fixed dose combination of brimonidine and timolol
CN103957887B (zh) 包含前列腺素F2α衍生物和透明质酸的眼用组合物
US10792288B2 (en) Preservative free brimonidine and timolol solutions
JP7365056B6 (ja) 眼充血を治療するための組成物およびそれを用いて眼充血を治療するための方法
US9889088B2 (en) Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
MX2011009802A (es) Formulaciones oftalmicas de cetirizina y metodos de uso.
WO2017066052A1 (en) Formulations and methods for treating high intraocular pressure
US8268824B2 (en) Therapeutic agent for corneal disease
US20070042951A1 (en) Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides
US20140275197A1 (en) Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes
WO2021210646A1 (ja) エピナスチン又はその塩を含有する水性組成物
WO2024135837A1 (ja) 組織移行性及び防腐効力を向上させるエピナスチン含有水性組成物
US20130210876A1 (en) Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
TR201612001A1 (tr) Anti̇glokom akti̇vi̇teye sahi̇p oftalmi̇k formülasyonlar

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1246689

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20171201

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1246689

Country of ref document: HK